연구동향 분석

Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer

정영신 김현수 이정윤 강원준 남은지 김성훈 김상운 김영태 2020년

논문상세정보
인용/피인용
' Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • neoadjuvant therapy
  • ovarian neoplasms
  • positron emission tomography-computed tomography
  • treatment outcome
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
361 0

0.0%

' Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer' 의 참고문헌

  • [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy
    Martoni AA [2011]
  • Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing
    Lee JY [2015]
  • Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma
    박준석 [2013]
  • Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas
  • Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma
    Fagotti A [2008]
  • Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer
    Petrillo M [2014]
  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS) : an open-label, randomised, controlled, non-inferiority trial
    Kehoe S [2015]
  • Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    Avril N [2005]
  • PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction : the MUNICON phase II trial
    Lordick F [2007]
  • PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus
  • Overview of early response assessment in lymphoma with FDG-PET
    MacManus MP [2007]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  • Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    Vergote I [2010]
  • Monitoring the neoadjuvant therapy res-ponse in gynecological cancer patients using FDG PET
    Nishiyama Y [2008]
  • Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
    이용재 [2019]
  • Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neo-adjuvant chemotherapy and debulking surgery
    Muraji M [2013]
  • Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer
    Sassen S [2007]
  • Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debul-king
    Le T [2007]
  • From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors
    Wahl RL [2009]
  • External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
    이정윤 [2017]
  • Early assessment with 18F-fluorodeoxyglucose posi-tron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer
    Groheux D [2014]
  • Correlation between therapy response assessment using FDG PET/CT and histopathologic tumor regression grade in hepatic metastasis of colorectal carcinoma after neoadjuvant therapy
    Burger IA [2013]
  • Chemotherapy response score : development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
    Bohm S [2015]
  • 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant che-motherapy in advanced epithelial ovarian cancer
    Vallius T [2016]